BioSpace News Archive

Medable Inc, the leading cloud platform for patient-centered drug development, announced the hiring of Andrea Valente as chief operating officer.

Scarlet brings diagnostic service to patients’ homes, offices and other preferred locations, delivering an on-demand, safe and convenient diagnostic experience for patients and healthcare providers

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported preliminary financial results for the three months and twelve months ended December 31, 2020.

Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it intends to offer and sell shares of its common stock in a “firm commitment” underwritten public offering.

BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, on the terms and subject to the conditions of their previously announced merger agreement, is expected to close on or about January 26, 2021.

Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial and operational results for the full-year ended January 2, 2021 and provided estimates for its full-year 2021 financial guidance.

Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, announced that it has appointed William White to its Board of Directors.

Prominent Orange County Physician Group Serving Thousands of Patients with Cancer and Blood Diseases Chooses to Join MemorialCare Medical Group, Expand Access to Local Medical Services

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $16.00 per share

Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, announced the pricing of an underwritten public offering of 6,842,106 shares of its common stock at a public offering price of $9.50 per share.